Aptimmune Biologics


Aptimmune Biologics is mucosal vaccine company developing novel swine vaccines aimed at combating the growing threat of PRRSV and influenza virus—estimated at an annual combined economic impact of $1.4 billion on the U.S. swine industry. Aptimmune’s new vaccine portfolio will change the management of these diseases, and significantly improve swine health and producer productivity.


Aptimmune Biologics is headquartered in Champaign, IL.


Aptimmune Biologics
Arsenal Capital Management – St Louis | Aptimmune Biologics
class="pirenko_portfolios-template-default single single-pirenko_portfolios postid-1209 samba_theme samba_left_nav samba_left_align samba_responsive wpb-js-composer js-comp-ver-5.1.1 vc_responsive"